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Abstract.  
 
Background: Primary endocrine therapy (PET) is used as an alternative to surgery in up to 40% of UK 
women with early breast cancer over age 70.  This study has investigated the impact of surgery 
versus PET on breast cancer specific survival (BCSS) in older women.  
 
Methods: Cancer registration data were obtained from two English regions from 2002 to 2010 
(n=23,961). A retrospective analysis was performed for women with ER positive disease, using 
statistical modelling to show the effect of treatment (surgery or PET) and age/health status on BCSS. 
Missing data was handled using multiple imputation. 
 
Results: After data pre-processing, 18,730 (78.5%) were identified as having ER positive disease;  of 
these, 10,087 (54%) had surgery and 8,643 (46%) had PET.   BCSS was worse in the PET group 
compared with the surgical group (5 year BCSS: 69% v 90% respectively).  This was true for all strata 
considered, though the differential was lessened in the cohort with the greatest degree of 
comorbidity. For older, frailer patients the hazard of breast cancer death has less relative impact on 
overall survival. Selection for surgery on the basis of predicted life expectancy may permit selection 
of women for whom surgery confers little benefit.  This model is being used to develop an on-line 
algorithm to aid management of older women with early breast cancer (Age Gap Risk Prediction 
Tool).    
 
Conclusion: BCSS in older women with ER positive disease is worse if surgery is omitted.  This 
treatment choice may, therefore, contribute to inferior cancer outcomes.  
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INTRODUCTION 
In the UK, women over the age of 70 account for more than 30% of all diagnoses of breast cancer(1). 
Treatment of older breast cancer patients in the UK differs from that recommended by National 
guidelines across the spectrum of therapy (2, 3). Rates of breast surgery for operable disease are 
lower in women aged over 70 than for younger patients (3, 4). In addition, practice varies by UK 
health region, with rates of surgery varying between 60% and 88%:  a difference that cannot be 
accounted for by case mix (5). 
 Older women in other developed nations, such as the Netherlands and the Republic of Ireland are 
less likely to receive surgery for breast cancer than their younger counterparts, but the discrepancy 
is lower than that observed in the UK(6, 7). In the USA rates of surgical treatment for stage I-II 
disease remain over 90% for patients aged 90 and over (8). 
Relative survival for breast cancer in the UK is inferior to that seen in a number of other developed 
nations, particularly in this older age group (9). This pattern persists after accounting for stage at 
diagnosis, suggesting that some of the discrepancy is due to suboptimal management rather than 
late presentation. 
For women with oestrogen receptor positive (ER+) operable breast cancer, primary endocrine 
therapy (PET) is the main alternative to surgery.  Primary endocrine therapy in this context is defined 
as treatment with an anti-oestrogen, such as tamoxifen or an aromatase inhibitor, without surgical 
intent.  Historic randomized trials of PET compared with surgery, both with and without adjuvant 
tamoxifen, suggested that in women aged 75 or over there was no evidence of a difference either in 
terms of overall (OS) or breast cancer specific survival (BCSS) between the two approaches at 5 year 
median follow up (10). On very long term follow up, survival outcomes in the non-surgical group 
were inferior(11), as would be expected considering that secondary anti-oestrogen resistance 
develops with time.   Evidence suggests,  that women in the 70-75 year age range may benefit from 
surgery even at 5 year follow-up (12). Local disease control was considerably worse with PET even 
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on short and medium term follow up (11-13), with a significantly greater number of patients 
requiring a change of management on disease progression. The trials were flawed by modern 
standards: patients with co-morbidities were excluded and the surgical arm therapies were often 
substandard with no adjuvant chemotherapy, and no chest wall or breast radiotherapy.  As a result, 
the trial populations did not reflect the heterogeneity in health states typical of the older population 
nor the sophistication of modern breast cancer care. Furthermore, these trials do not reflect the 
advances in surgical and anaesthetic techniques, the introduction of third generation aromatase 
inhibitors or the increase in life expectancy over the last four decades (from 75.3 years  in 1971 to 
83.2 years in 2012-14)(14).  Rates of mortality and morbidity from modern day breast cancer surgery 
were very low in a recent  National UK audit, suggesting that surgery is safe in the majority of older 
woman (15).  These historic trials may no longer fully represent modern practice and outcomes. 
 
A recent review of evidence from non-randomised cohort studies has suggested that surgery may be 
more effective than PET in terms of BCSS (10). Cohort studies are often better able to include 
representative populations, and provide information on outcomes of treatment in a “real world” 
clinical setting. However, the studies included in this review did not attempt to account for the 
differing patient characteristics between women treated with surgery and those with PET. On 
average, women are more likely to receive PET if they are older and have chronic comorbidities (16, 
17). This confounds overall survival estimates and will increase non-breast cancer mortality in the 
non-surgically treated patients. Similarly, disease characteristics such as stage at diagnosis and 
tumour grade are associated with treatment choice.  Bates and colleagues (2014) found that large 
tumour size (>5cm) and node positivity were associated with non-surgical treatments suggesting 
that selection bias by stage of disease may confound the outcomes of observational studies in 
favour of surgery (17).   In addition women who have surgery are usually those with early stage 
disease as surgery is not appropriate or possible in advanced breast cancer.  Outcomes in the non-
surgical group may appear worse if women with advanced disease remain under-staged and are 
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mistakenly categorised as having early stage disease. This causes confounding in estimates of breast 
cancer specific survival.    Observed differences in outcomes seen in these cohort studies cannot, 
therefore, be assumed to be solely due to treatment.  Another issue in observational data is that 
cause of death may be misclassified as due to breast cancer whereas in a randomised trial efforts to 
establish the actual cause of death may be more rigorous.    
There are significant barriers to conducting sufficiently powered randomised clinical trials in older 
breast cancer patients (18). The Endocrine+/- Surgical Therapy for Elderly women with Mammary 
Cancer trial (ESTEeM) was a recent attempt to conduct an age and fitness stratified randomised trial 
to compare these treatment approaches. It failed, with the study closing in 2009, due to slow 
recruitment (18). In light of this, it is necessary to make use of observational evidence, combined 
with mathematical modelling, to adjust for issues such as confounding, in order to assess how 
treatment choices impact on outcomes. 
 
The aim of this study was to investigate how current UK practice in the surgical treatment of older 
women (age >70 years) with breast cancer affects breast cancer survival at the population level. A 
retrospective cohort analysis was conducted using UK Cancer Registry data.  The data were routinely 
collected from two English cancer registration regions which are demographically representative of 
the wider UK population (West Midlands and Northern & Yorkshire). The effect of PET versus 
surgical treatment on survival outcomes was assessed using exploratory data analysis and survival 
analysis methods.  
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METHODS 
Data 
Data on all first diagnoses of invasive breast cancer in women aged 70 and over between the years of 
2002 and 2010 were acquired from two UK cancer registry regions (West Midlands, Northern & 
Yorkshire). Variables provided for analysis are shown in Table 1.   The patient and disease variables 
are representative of wider UK National data in terms of the age distribution, deprivation pattern,  
tumour stage and biological sub-type distributions.   Survival data was derived from death 
certifications from the Office for National Statistics. Time to death was defined as the difference in 
days between the date of diagnosis and the date of death. Patients who remain alive were censored. 
Cause of death was recorded by the registry as either “breast cancer”, “other (cancer)”, “other (non-
cancer)”, “other (unknown)” or “unknown”. For the purposes of this analysis, deaths were classified 
dichotomously as either “breast cancer” or “not breast cancer”.  
The data presented in Table 1 had been pre-processed as described in Supplemental Materials. In 
particular,  oestrogen receptor (ER) status was not completely recorded for all patients, 
predominantly in the Northern and Yorkshire region.  In the West Midlands 14.5% of patients had 
missing ER status data over the 2002-2010 period;   in the Northern & Yorkshire region ER status was 
not available for patients diagnosed before 2010; in 2010 35% of patients had missing data.  Patients 
with missing ER status who had received hormone therapy were assumed to have had ER+ disease. 
This was justified by the fact that hormone therapy is only effective for and offered to ER+ patients, 
which was routinely tested for throughout this time period and therefore it is reasonable to suppose 
that hormone therapy would not have been given to women with ER negative tumours. Previous 
internal data quality audits by the cancer registry have shown that hormone therapy data is reliable 
for the Northern & Yorkshire region. 
Data on surgical procedures were available from linked records of treatment episodes. These include 
the OPCS4 code of the procedure(s) received along with the date of the episode. A patient was 
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classed as receiving primary surgery if they had an episode including a procedure indicating breast 
surgery recorded within 6 months of diagnosis. Comorbidity was derived from linked records in the 
Hospital Episode Statistics dataset and aggregated using the Charlson Co-morbidity Index (CCI)(19) 
by counting diagnostic codes recorded in episodes in the 18 months prior to diagnosis, an approach 
used in other studies using routine registration data(20). 
 
[INSERT TABLE 1]  
 
Statistical analysis 
Exploratory survival analysis consisted of plotting cumulative incidence curves for breast cancer and 
other cause mortality for patients treated surgically and non-surgically. The effect of treatment and 
other covariates on breast cancer specific survival were estimated using two models. The first was 
the commonly used Cox proportional hazards model (21), which estimates the effects of covariates 
on survival outcomes but makes no assumptions about the shape of the underlying survival curve. 
The second was the Royston-Parmar model,(22) which relaxes the proportional hazards assumption, 
allowing the effect of a covariate to vary over time. On the basis of exploratory analysis, the effects 
of age at diagnosis and treatment options (surgery or PET) were modelled as time varying and the 
others were modelled as time invariant.   It also specifies a flexible functional form for the 
underlying hazard, making it easier to extrapolate to predictions of future outcomes.  
The registry data contained a number of variables with a non-negligible proportion of missing values 
(Table 1). If every patient with any missing data had been excluded from analysis, a lot of useful 
information would have been lost.  Also, because the ‘missingness’ is often dependent on patient 
characteristics, results would be biased by the exclusions.  To mitigate these issues, the method of 
multiple imputation was used prior to fitting the models.  For each patient where one or more 
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variables were missing, the distribution of those variables in patients with similar characteristics was 
used to impute values for the missing variables.  In this way the dataset was completed in a 
probabilistically plausible way.  In order to account for the randomness in completing the dataset in 
this way, the multiple imputation was repeated to create a collection of 1000 completed datasets.  
The modelling was carried out on each of these complete datasets and the results combined to 
produce a final result which makes maximal use of the information in the data but avoids the bias of 
being based on any individual imputed dataset.  Further details of the imputation process are 
included in supplemental materials. 
 
Exploratory analysis and derivation of the final models were carried out using the open-source 
statistical package R (version 3.0.1)(23). The user-contributed CRAN R package “mi” was used to 
implement the method of multiple imputation with chained equations (24). The Royston Parmar 
model was implemented using Stata 13 (StataCorp. 2013), via the module “stpm2”(25).  
 
RESULTS 
The cumulative incidence of breast cancer and other cause mortality for patients treated surgically 
and non-surgically were derived, after removing patients with ER negative disease and early deaths 
(within 91 days) (Figure 1).  Non-breast cancer causes of death predominate in the PET group, due to  
frailer, less fit women being less likely to have surgery.   
 
[INSERT FIGURE 1] 
 
Five year breast cancer specific survival (BCSS) in the PET and surgery arms was 69% and 90% 
respectively.  Figures 2 and 3 shows the Kaplan Meier estimates for BCSS by stage and for unknown 
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stage at diagnosis (Figure 2), by age group (Figure 3, left) and by number of co-morbidities (Figure 3, 
right).  The curves by stage demonstrate that BCSS was inferior in patients treated with PET 
compared to those who received surgery, regardless of stage at diagnosis. Figure 2 shows that for 
patients with missing stage at diagnosis (bottom right) there was a sharp drop in BCSS in the first 
few months for patients who are treated with PET. This may reflect the fact that some patients in 
this group had undiagnosed advanced disease at diagnosis as mentioned above.   The curves in 
Figure 3 demonstrate that BCSS remained inferior for patients receiving PET despite increasing age.  
The same is true for increasing numbers of co-morbidities, except for those in the highest 
comorbidities category.  Here the degree of separation between outcomes and the width of the 
confidence intervals is less distinct.   It is less clear that the PET choice had a detrimental effect in 
this group. 
 
[INSERT FIGURE 2] 
 
[INSERT FIGURE 3] 
 
The survival models were fit to the datasets following multiple imputation.  The results of the Cox 
proportional hazards (Table SM3) and Royston Parmar model (Table 2 and Figures 4 and SM1) 
demonstrate the effect of treatment and other covariates on BCSS. The estimates from the Cox 
model indicate that the hazard of BC mortality is lower in patients treated surgically. Tumour grade, 
nodal involvement and method of detection also have a strong influence on this outcome, with 
grade 3 disease and node positivity associated with inferior BCSS and screen detection being 
associated with better BCSS. Similar results are seen in the Royston Parmar model. The hazard ratio 
for surgical treatment on breast cancer specific survival, from the Royston Parmar model is shown in 
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Figure 4. The hazard ratio is approximately constant at around 0.37 from year 3 onwards. Hazard 
ratios for other covariates from the Royston Parmar model (Table 2) show that, as would be 
expected, patients with higher grade, larger tumour size, and nodal involvement have a higher 
hazard of breast cancer mortality. Screen detection is associated with a considerably lower hazard of 
breast cancer mortality. There are also small increases in breast cancer mortality associated with 
increased numbers of comorbidities and with income deprivation. 
 
[INSERT TABLE 2]  
 
[INSERT FIGURE 4] 
 
 
 
DISCUSSION 
The results of this analysis show that in a retrospective cohort of older breast cancer patients with 
ER+ disease in the UK, the hazard of breast cancer death was greater in patients treated with PET 
than those who received surgery. Assuming this reflects a true underlying difference in the hazard 
between the two treatment approaches, this will translate into a difference in overall survival. This 
difference is greatest in patients who would otherwise have a high underlying life expectancy, i.e. 
younger and healthier patients. For older, frailer patients, the high risk of death from non-breast 
cancer causes means that the hazard of breast cancer death would have less relative impact on 
overall survival, so the effect of non-surgical treatment on survival outcomes would be smaller. In 
some patients, the difference may be so small that PET would be the preferred treatment option in 
order to avoid any potential morbidity associated with surgery. Given that the registry data contains 
only limited data on underlying health status, it is unsafe to compare the groups in terms of overall 
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survival since many of the observed differences may be explained by unobserved confounding 
variables. Comparisons of BCSS should be less prone to this issue as the observed disease 
characteristics would be expected to have a more significant effect on this outcome. Higher rates of 
PET treatment in the UK than in many other developed countries could explain, at least in part, the 
inferior relative survival for breast cancer in the UK compared with a number of other developed 
nations in this age group. 
The findings of this analysis show similar findings to that of another UK cohort study. This large study 
(n= 1065) looked at outcomes for a cohort of patients aged 70+ recruited between 1973 and 2009 at 
a single specialist centre in Nottingham, England(26). This study also demonstrated that at a 
population level there was a difference in BCSS between patients treated with PET and surgery. 
However, the magnitude of the difference was smaller than that observed in our registry cohort and 
estimates of BCSS were also higher in both the surgery  and PET arms (95% and 84% respectively) 
compared with the registry cohort (90% and 69% respectively).  Our data are from a larger cohort 
from multiple sites, rather than one single site and may therefore be more representative of practice 
across the whole country. In addition, the Nottingham cohort included very ER rich early operable 
cancer; a subgroup analysis suggested that for women with strongly ER+ tumours (H Score >250) 
there was no difference in the effectiveness of the two approaches. The H score was not available 
for the registry cohort so an equivalent analysis was not possible. The historical clinical trials 
comparing these treatment options suggested there was limited difference in effectiveness between 
the two approaches, however ER status was not measured in the majority of the trials. These trials 
are perhaps no longer fully representative of modern practice and outcomes, as detailed above.  
Even well conducted randomised trials are prone to external biases owing to issues of 
generalisability; due, for example, to exclusion of patients with certain characteristics or deviations 
from everyday clinical practice. Routine registration datasets reflects outcomes as observed in real 
life clinical practice; for example, compliance and adherence to endocrine therapy is likely to be 
worse in everyday practice than in a clinical study where treatment is more closely monitored. 
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Routinely collected data has the advantage of reflecting outcomes observed in clinical practice; 
registry data do, however, have some quality issues. There are a high proportion of missing values 
for a number of covariates, especially for patients in the non-surgical group. For example, tumour 
size and clinical node status is not always recorded from imaging reports in these patients. Missing 
data was addressed using multiple imputation. This approach helps to mitigate against biases which 
can occur if patients with missing data are excluded and the missing data is connected to the 
characteristics of the individuals. This contrasts with the complete case analysis approach taken by 
other models in the breast cancer field, for example PREDICT(27).  However missing data was less of 
an issue for the PREDICT model, which is based only on women treated surgically and includes 
younger patients who are more likely to have complete data. In the present study, staging data is 
missing for a number of patients; patients treated non-surgically are more likely to have incomplete 
staging information as non-pathological staging information has historically not always been 
recorded. Exclusion of all patients with missing stage at diagnosis would bias results as the remaining 
sample would not be representative of the population as a whole. Inclusion of all patients with 
missing stage would also be expected to bias results; poorer survival outcomes in the PET group may 
result due to the inability to identify all patients who were treated non-surgically due to the 
presence of advanced stage disease. For this reason, multiple imputation was performed using the 
whole dataset.  In each imputation, patients with actual or imputed Stage IV disease were excluded. 
The technique of multiple imputation used in this study has the advantage of propagating the 
uncertainty due to missing data into the estimates of covariate effects.. This is an attempt to avoid 
the biases which may occur when patients with missing data are excluded from analysis (and the 
missing data is connected to the characteristics of the data). This method is less prone to bias than 
other approaches to analysing registry data such as complete case analysis or treating “missing” as a 
category in a factor variable.   There is, however, no perfect method for accounting for missing data 
and it may not have accounted for all biases. Analysis of the multiple imputed datasets did not raise 
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any concerns about the validity of the imputation approach. However, by definition it is not possible 
to compare against the true underlying values.  
Observational studies are at risk of confounding between treatment allocation and outcomes, which 
leads to bias in estimates of treatment effects. The statistical techniques used in our study mitigate 
against confounding that is due to factors observed in the dataset. However, these techniques will 
not fully account for the effects of confounders which are not observed in our dataset, especially if 
there are confounders which are uncorrelated to observed covariates. With respect to BCSS, it was 
hypothesized a priori that disease characteristics and age were primary confounders between the 
outcome and treatment choice. On the other hand, unobserved characteristics such as frailty, which 
is not routinely collected by the registry may be accounted for in part due to its correlation with age 
and comorbidity and so are partially adjusted for in the various models. As a result, the key finding in 
the present study are unlikely to be explained as being primarily due to confounding.  By contrast, it 
is clear that these (health) factors could have a strong confounding effect with respect to death from 
non-breast cancer causes, and so overall survival was not considered. 
The Kaplan-Meier curves for BCSS suggest a sharper drop in the survival curve in the early part of the 
curve for the PET group, reflecting a number of early breast cancer deaths in this group.  This pattern 
is not observed in comparable studies; for example, in the Nottingham cohort the difference in BCSS 
grows slowly over time for both groups. One possible explanation for this is potential inaccuracy in 
recording of metastatic disease in the cancer registration data; for example it may not be updated if 
stage IV cancer is detected as a result of follow up staging tests. This may also be due to avoidance 
of surgery in the very frail and ill, who die of other causes soon after diagnosis.  Cause of death may 
be reported inaccurately. It is difficult to attribute death to a single cause, especially in the frail 
elderly, and in routine data breast cancer may be listed as the primary cause of death in cases when 
in fact other causes were the primary contributor. Further research is needed to determine the 
extent to which routine data can be used to accurately model survival outcomes in this population; 
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for example by collecting routine registration data alongside data collected specifically for a clinical 
study. 
 
CONCLUSION 
Our analysis suggests that for older breast cancer patients with ER+ disease, the hazard of breast 
cancer death was greater in patients treated with PET than those who received surgery. This appears 
to contrast with RCT data from historic trials although a trend in favour of surgery was shown on 
meta analysis (5, 28) and a significant advantage for surgery was shown  on long term follow up of 
these studies (11), so the outcome is not discordant.  Our findings suggest that surgery should be 
recommended for the majority of women, with PET being reserved for women with limited life 
expectancy (due to age, frailty or co-morbidity) or those who express a preference not to undergo 
surgery. Findings from this analysis have been used to develop a web-based clinical management 
algorithm to help clinical teams decide on best practice for an individual older woman. Evaluation of 
this tool is ongoing and the data from this study are of value in predicting what may be expected for 
individuals where different treatment options are being considered even though a causal effect can 
not be ascertained due to the non randomised nature of the data.  An ongoing prospective cohort 
study, part of the  Bridging the Age Gap in Breast Cancer (BTAG) project(29),  will provide a more 
detailed dataset to help assess the effects of surgery in older women on survival and recurrence. The 
research programme is also developing and evaluating a series of decision support instruments, 
tailored to older women, to support them in deciding between surgery and PET.  This will be 
targeted at those women where both options are likely to give good outcomes. 
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TABLES & FIGURES 
 
Table 1. Variables provided for analysis after pre-processing as described above and in Supplemental 
Materials. ER Status is shown for completeness but ER- tumours were excluded from further 
analysis.  Missing values for grade, size, nodal status and comorbidities were addressed, prior to 
modelling, using multiple imputation as described in Statistical Analysis. Patients with stage IV 
disease or who died within 91 days of diagnosis were excluded after the multiple imputation (as 
likely to have had advanced disease or be unlikely to benefit from breast cancer treatment). 
 
 n=23849 100.0% 
Region   
North Yorkshire 12916 54.2% 
West Midlands 10933 45.8% 
Age at diagnosis   
70 - 74 6401 26.8% 
75 - 79 6328 26.5% 
80 - 84 5513 23.1% 
85 - 89 3662 15.4% 
90 - 94 1483 6.2% 
95+ 462 1.9% 
Deprivation quintile   
1 (least deprived) 3861 16.2% 
2 4868 20.4% 
3 4761 19.9% 
4 5060 21.2% 
5 5299 22.2% 
Detection route   
Screen detected 1345 5.6% 
Symptomatic 22504 94.4% 
19 
Tumour stage   
I 5142 21.6% 
II 8445 35.4% 
III 1872 7.8% 
IV 1511 6.3% 
Missing 6879 28.8% 
Tumour diameter (mm, invasive 
component)   
[0,10) 972 4.1% 
[10,20) 4584 19.2% 
[20,50) 8487 35.6% 
50+ 1370 5.7% 
Missing 8436 35.4% 
Grade   
1 3120 13.1% 
2 10482 44.0% 
3 5746 24.1% 
Missing 4501 18.9% 
Nodal status   
Negative 6549 27.5% 
Positive 5581 23.4% 
Missing 11719 49.1% 
ER status   
Negative 5119 21.5% 
Positive 18730 78.5% 
20 
HER2 status   
Negative 4758 20.0% 
Positive 850 3.6% 
Missing 18241 76.5% 
Comorbidity score   
0 16688 70.0% 
1 1882 7.9% 
2 979 4.1% 
3+ 550 1.8% 
Missing 3750 15.7% 
Breast surgery   
No 10475 43.9% 
Yes 13374 56.1% 
Chemotherapy   
No 22675 95.1% 
Yes 1174 4.9% 
Radiotherapy   
No 15759 66.1% 
Yes 8090 33.9% 
Hormone therapy   
No 8558 35.9% 
Yes 15291 64.1% 
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Table 2. Estimate of non-time-varying hazard ratios for breast cancer mortality from the 
Royston Parmar restricted cubic spline model 
  Hazard ratio 
Lower  
95% CI 
Upper  
95% CI p value 
Comorbidity (per Charlson index 
point) 1.091 1.02 1.168 0.010 
Symptomatic detection v screened  2.691 1.84 3.896 <0.001 
Deprivation quintile 2 v 1  1.116 0.961 1.297 0.170 
Deprivation quintile 3 v 1  1.105 0.951 1.297 0.213 
Deprivation quintile 4 v 1  1.094 0.942 1.271 0.264 
Deprivation quintile 5 v 1  1.259 1.094 1.448 0.001 
Grade 2 v 1  1.391 1.185 1.632 <0.001 
Grade 3 v 1  2.886 2.46 3.421 <0.001 
Node positive v node negative  2.014 1.804 2.248 <0.001 
Tumour size (per mm diameter) 1.011 1.008 1.013 <0.001 
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Figure 1: Cumulative incidence of breast cancer and other cause mortality for surgery and 
primary endocrine therapy( PET) treatment arms.  Non-breast cancer causes of death 
predominate in the non-surgical group, due to the frailer, less fit women being less likely to 
have surgery.  Five year breast cancer specific survival in the PET and surgery arms were 
69% and 90% respectively.  
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Figure 2: Kaplan Meier estimates for breast cancer specific survival (BCSS) by stage at diagnosis 
and for unknown stage for surgery and PET treatment arms. These curves demonstrate that BCSS is 
inferior in patients treated with PET compared to those receiving surgery, regardless of stage at 
diagnosis. The sharp drop in BCSS in the first few months for patients with missing stage (bottom 
right) who are treated with PET may reflect the fact that some patients in this group have advanced 
disease at diagnosis.   
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Figure 3: Breast cancer specific survival (BCSS) by age group (left) and by comorbidity score (right) 
for surgery and PET treatment arms. These curves demonstrate that BCSS remains inferior for 
patients receiving PET despite older age or increasing numbers of co-morbidities. 
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Figure 4: Time varying hazard ratio for breast cancer specific mortality for surgery versus PET 
treatment arms from Royston-Parmar model. The hazard ratio is approximately constant at around 
0.37 from year 3 onwards 
 
 
 
 
